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CASE PRESENTATION
A 36-year-old patient complained of progressing fatigue,
lack of appetite, and weakness for a few weeks, for which
he had been using paracetamol (acetaminophen)
intermittently. He was referred to our center from another
hospital with hemolysis, thrombocytopenia, and acute
renal failure (ARF). On admission, the patient did not
complain of any specific additional symptoms. Besides
paracetamol, he had not received any other medication.
The patient reported flu-like symptoms 3 months before
admission. The family history was unremarkable. Physical
examination revealed a pale-looking patient (180 cm; 81 kg)
with icteric sclerae. He was tachycardic (110 heart beats per
min) and had elevated blood pressure (155/90 mm Hg). No
other physical abnormalities were detectable.
Laboratory investigations are depicted in Table 1. Specific
analyses: von Willebrand factor cleavage protease activity
31% (40–120%), von Willebrand Factor Multimere negative,
antibodies to von Willebrand Factor cleavage protease
negative, factor H 614 mg l1 (345–590 mg l1). Western blot
analyses with patient’s serum revealed the presence of
complement factor H (CFH) and complement factor H-like
protein 1 (CFHL1), but no detectable levels of complement
factor H-related proteins 1 and 3 (CFHR1 and CFHR3) (Figure
1a). Antibodies to CFHR1 were negative. Genetic analyses1
showed no CFH mutation, but revealed homozygous deletion
of a 83 kb genomic fragment representing CFHR3 and CFHR1
(Figure 1b). Kidneys were of normal size with increased
density by ultrasound examination. Electrocardiography
revealed ischemic changes posteroseptally, and hypertrophy
of the left ventricle was diagnosed by echocardiography.
RENAL BIOPSY
Renal biopsy contained 32 glomeruli. Several glomerular
segments and preglomerular arterioles were occluded by
hyaline thrombi as verified by immunohistology (Figure 2a
and b). By electron microscopy (Figure 2c and d), glomeruli
showed segmental detachment of endothelial cells from the
basement membrane, with loss of fenestrae. Mesangial edema
and segmental mesangial matrix increase could be observed.
The tubulointerstitial compartment was characterized by focal
interstitial fibrosis with collapsed tubules with broadened
basement membranes. Mononuclear cells were irregularly
distributed in these areas; interstitial fibrosis and atrophy were
estimated at 30–40%. By immunohistology applying the
alkaline phosphatase anti-alkaline phosphatase (APAAP)
method, a strong signal for fibrinogen/fibrin could be seen
in thrombi and along glomerular capillaries (Figure 2b).
CLINICAL DIAGNOSIS AND DIFFERENTIAL DIAGNOSES
Atypical D() hemolytic uremic syndrome (HUS) with ARF,
chronic interstitial fibrosis, and myocardial ischemia.
The triad of ARF, hemolytic anemia, and thrombocyto-
penia may be seen in severe sepsis, disseminated intravascular
coagulation, rheumatic systemic disorders, heparin-induced
thrombocytopenia, malignant hypertension, and thrombotic-
thrombocytopenic purpura (TTP).1 The first three diagnoses
could be excluded because of clinical history and clinical
chemistry analyses. Heparin-induced thrombocytopenia
could be excluded owing to non-exposure. Because of the
high shear forces generated by high blood pressure,
schistocytes may form in malignant hypertension, but not
in large numbers, as they are to be found in thrombotic
microangiopathies.1 Severe deficiency of ADAMTS13 (a
disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13) has been identified mostly in those
cases described clinically as TTP. However, distinction of TTP
and HUS based on ADAMTS13 activity is not without
criticism,2 and should rather be based on clinical manifesta-
tions.3 Moreover, results from ADAMTS13 activity measure-
ment are often time-delayed and therapeutic decisions should
thereof be made independently.
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CLINICAL FOLLOW-UP
Plasma exchange (PE) using fresh frozen plasma was initiated
with 3000 ml of plasma per session (B40 ml plasma per kg
body weight). In addition, 1 mg per kg body weight
prednisolone was given. After transfusion of two units of
erythrocyte concentrates, Hb increased to 9.0 g per 100 ml.
However, ischemia typical ECG changes did not disappear
until the fourth PE (Hb 9.1 g per 100 ml). Daily PE was
continued until day 23 and then stepwise reduced over the
subsequent 10 weeks. The blood pressure was controlled
initially (first 8 weeks) with metoprolol and moxonidin,
thereafter with metoprolol and benazepril. The left ventri-
cular hypertrophy suggested a so far unrecognized arterial
hypertension possibly caused by subclinical kidney involve-
ment of the underlying disease. However, this is speculative.
Under this therapy, creatinine clearance improved to
54.4 ml min1 and serum creatinine of 2.3 mg per 100 ml,
respectively. Although renal function stabilized, persistent
proteinuria was noted with 2520 mg day1 after 14 weeks.
Thus, a dual blockade of the renin–angiotensin system with
benazepril and valsartan in addition to metoprolol and
amlodipin was administered with blood pressure controlled
to mean values about 120/80 mm Hg, whereas moxonidin
was withdrawn. Subsequently, the patient developed two
relapses with increased hemolytic activity, platelet and
Table 1 | Relevant laboratory values
Patient Normal range
Hemoglobin 5.0 g per 100 ml 13.5–17.5 g per
100 ml





Free hemoglobin 33.1 mg per 100 ml p10 mg per 100 ml
Creatinine 6.7 mg per 100 ml 0.6–1.1 mg per 100 ml
BUN 78 mg per 100 ml 8–21 mg per 100 ml
Creatinine clearance 15 ml min1 80–160 ml min1
Phosphorous 1.77 mmol l1 0.7–1.4 mmol l1
Uric acid 14.1 mg per 100 ml 3.5–7.4 mg per 100 ml
Bilirubin 2.1 mg per 100 ml p1.2 mg per 100 ml
Glutamat-oxalacetat-
transminase
67 U l1 o25 U l1
Lactate
dehydrogenase
1824 U l1 p232 U l1
Haptoglobin o0.1 g l1 0.45–2.05 g l1
Creatine kinase 362 U l1 p270 U l1
Creatine kinase
(myocard type)
24 U l1 p17 U l1
Complement C3c 0.49 g l1 0.9–1.8 g l1
Urinalysis Blood +++,
protein +++












Proteinuria 3950 mg day1
(albumine 1010 mg l1,
a1-microglobuline
59 mg l1, IgG
93.1 mg l1)
o200 mg day1
BUN, blood urea nitrogen.











Figure 1 | Western blot analysis for complement factor
H-related protein 1 (CFHR1) and CFHR3 and deletion of a
chromosomal 83 kb fragment in DNA derived from the
patient. (a) Plasma (Pa) of the patient was separated by
SDS-PAGE, and analyzed by western blotting using an antiserum,
that identifies factor H (150 kDa) and CFHR1 (42 and 37 kDa) (lane
2) or CFHR3 (55 kDa) (inset). In the patient’s (Pa), the two CFHR1
forms and CFHR3 are absent. (b) Both alleles of the patients
include all the exons of the CFH and CFHR4 genes, but show
deletion of the CFHR3 and CFHR1 genes. Analyses of the genetic





Figure 2 | Histological changes seen in renal biopsy.
(a) Glomerulus with occlusion of capillaries by hyaline thrombi in
25% of capillary convolute (arrowhead). Two transverse sections
of afferent arteriole show a complete obliteration by hyaline
thrombus (arrows). There is focal interstitial fibrosis surrounding
tubules with broadened basement membranes (PAS staining,
original magnification  200). (b) Tangential and transverse
section of arterioles with thrombus, positive for fibrinogen/fibrin
(APAAP, original magnification  400). (c) Transmission electron
micrograph of glomerulus, endothelium is segmentally detached
from glomerular basement with electrolucent subendothelial
space. Fenestrae are lost. Foot processes of podocytes are often
plumb and only rarely effaced. (TEM, original magnification
 3000; Zeiss EM 900). (d) Arteriole with occlusion of lumen by
debris and fibrin, endothelium is necrotic as are some smooth
muscle cells. (TEM, original magnification  3000; Zeiss EM 900
(Jena, Germany)).
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complement component C3c decreases, and further dete-
rioration of renal excretory function within 6 months after
his first discharge from our hospital. These relapses were
again treated with additional cycles of daily PE, followed each
time by reductions of disease activity. However, a slight
hemolytic activity (elevated lactate dehydrogenase, decreased
haptoglobin levels, and presence of schistocytes) persisted
and renal function deteriorated to a creatinine clearance
between 27 and 42 ml min1. In view of persistent hemolysis,
twice-weekly maintenance PE was prescribed. With this
regimen, lactate dehydrogenase was almost normal (range
235–285 U l1) and platelets were within normal range,
although haptoglobin remained decreased below 0.1 g l1.
Attempts of reducing the frequency of PE resulted in
immediate relapses. Thus, maintenance PE has been
continued for a period of 19 months as of the date of this
report resulting in a stabilization of renal function (current
creatinine clearance 51 ml min1) (Figure 3).
DISCUSSION
History, epidemiology, and classification
In 1955, Gasser4 coined the term ‘hemolytic uremic
syndrome.’ HUS is characterized by thrombocytopenia,
hemolytic anemia, and low platelet count. Commonly
accepted parameters and terms for describing different forms
of HUS are still lacking. It is now accepted to classify HUS
based on the presence or absence of prodromal diarrhea.
HUS with prodromal diarrhea is called typical HUS (also
called epidemic or D(þ )HUS). HUS without prodromal
diarrhea is called atypical HUS (also called sporadic or
D()HUS).1,5 The idiopathic (atypical) D()HUS is the
most common form of microangiopathy with renal failure in
adults.1 D()HUS is rare, may be familial, and has a poorer
prognosis, with death rates of up to 25% in the acute phase
and 50% requiring ongoing renal replacement therapy.6
Clinical manifestation of HUS
ARF may vary from simple hematuria, proteinuria to severe
oliguria. ARF with anuria has been reported in HUS in 40%
of patients, and up to 61% have to undergo dialysis. Other
systems affected include central nervous system, gastrointest-
inal tract, liver, and pancreas.7 Fever and neurological
dysfunction are more commonly found in patients with
TTP but have been described in HUS as well. Similarly, the
presence of pathologic lesions in pancreas, brain, adrenal
glands, and heart was significantly more common in TTP, but
can also be found in HUS.8
Pathology
In D()HUS, the predominant pathological abnormality is
found in the renal arterioles and glomeruli. There is
widespread endothelial swelling with cell retraction leading
to exposure of the basement membrane. The vessel lumens
are occluded by platelet fibrin thrombi.6,9 Interestingly,
plasma of patients with D()HUS, but not with D(þ )HUS
induced apoptosis of endothelial cells and expression of Fas
in microvascular endothelial cells of renal origin.1,10
Pathogenesis and diagnosis of HUS
D()HUS is characterized by activation of the complement
cascade via the alternative pathway. Classically, laboratory
investigations reveal a decrease of complement component
C3 but normal C4, as it was the case in our patient.11 The
alternative pathway of complement represents a safeguard
system in humans, which is initiated in the fluid phase by the
spontaneous generation of an enzyme that cleaves C3, that is
by the first C3 convertase. The activated complement system
has devastating effects, therefore important control and
inhibitory reactions exist on host cells, which keep the system
on track and provide local protection of host surfaces and
cells. This local control ensures that activation is specifically
targeted to foreign surfaces. Defective complement control is
linked to HUS.12 Formation and activity of the alternative
pathway amplification convertase C3bBb is tightly controlled
both in the fluid phase and on the surface of host cells or
tissues (Figure 4). Four potent regulators are expressed on the
surface of host cells, that is, CR1 (CD35), MCP (membrane
cofactor protein, CD46), DAF (decay accelerating factor,
CD55) and CD59.11,13 Potent regulators are also found in the
fluid phase consisting of the members of the factor H protein
family. This family of structurally and immunologically
related proteins includes factor H (CFH), factor H-like
protein 1 (CFHL1), and six complement factor H-related
proteins (CFHR) denoted CFHR1, CFHR2, CFHR3,
CFHR4A, CFHR4B, and CFHR5.14,15,16 The fluid phase
regulator CFH is an important and potent inhibitor of the
amplification cascade of complement activation. It is
estimated that CFH in combination with factor I controls
more than 99% of complement activity.13 All these proteins
are synthesized primarily in the liver and are secreted into
plasma.16 The functional properties of CFHL1 and CFHR





























Figure 3 | Time course of creatinine clearance and PE therapy.
There is an initial improvement with subsequent stabilization of
renal function under intermittent PE during the last 19 months.
Relapse of HUS (arrow); daily PE (drawn line); intermittent plasma
exchange (dotted line).
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regulatory properties homologous to CFH.13 A possible
diagnostic algorithm of atypical HUS is shown in Figure 5.
None of the identified disease-associated complement genes,
however, can be considered as the initial trigger, which
initiates reactions that cause tissue damage and atypical HUS.
Thus, the initial trigger of HUS remains a matter of
speculation: it may be an infectious agent or an inflammatory
stimulus that activates complement locally.12 These trigger
mechanisms include infection with neuraminidase-produ-
cing Streptococcus pneumoniae or HIV, pregnancy, rheuma-
tological disorder, malignancy, combined methylmalonic
aciduria and homocystinuria, a previous type of transplants,
especially hematopoietic cell transplantation as well as the
treatment with several drugs.9 However, all this could be
excluded in our patient.
CFHR in HUS
To date, similarities have been observed in the ability of
CFHRs to bind C3b in homology to CFH.14 In our patient,
we found a deficiency of CFHR1 and CFHR3. Deficiency of
CFHR1 and CFHR3 was identified as risk factors for the
appearance of atypical HUS in one study. In cohort analyses,
the absence of CFHR1 and CFHR3 has been identified in
16–28% in patients with atypical HUS identifying a
homozygous and heterozygous genomic deletion as possible
causes.17 The functional relevance has been shown in three
CFHR1/CFHR3-deficient patients from whom heat-inacti-
vated serum increased erythrocyte lysis. These data showed
that CFHR1/CFHR3-deficient plasma reduce protective
activity and suggested that the absence of CFHR1 and/or
CFHR3 contributes to the defective regulation of comple-
ment activation on cell and tissue surfaces.17
Treatment of CFHR deficiency-related HUS
The time course of patients with CFHR1/CFHR3 deficiency
has been described in only three individuals at the age of
11–13 years, whose disease activity could be controlled by PE,
intravenous plasma infusion, corticosteroids, and antihyper-
tensives for 1–4 years.17,18 Our case is the first description of
an adult patient with a CFHR1/CFHR3 deficiency who is
followed over an extended period of 19 months. Despite PE
twice a week, laboratory investigations revealed a slight
continuous disease activity without an apparent further
damage in the kidney as assessed by stable renal function
parameters. In a previous study, it has been speculated how
this deficiency exerts disease-modifying action. One explana-
tion was that CFHR1 and CFHR3 have cofactor-enhancing
activity for CFH. On the other hand, a regulatory function in
C3b processing was discussed, as CFHR3 binds C3b and
heparin.19 Another possibility was that the deletion is in
linkage disequilibrium with other susceptibility alleles in
CFH or that it may affect CFH transcription.17,19
CONCLUSION
The time course of chronic atypical HUS due to a deficiency
of CFHR1 and CFHR3 can be positively influenced by regular
PE, resulting in disease remission over a long period and
stabilization of renal function. However, the long-term
prognosis remains unclear.
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Figure 4 | Activation steps of the alternative pathway of
complement. The alternative pathway of complement is initiated
spontaneously by a conformational change of the C3 protein.
After binding of factor B and conversion to Bb, the resulting C3Bb
fragment forms an active complement convertase that generates
more C3b. At the surface, C3b is generated, which deposits onto
the surface. In the absence of regulator’s activation proceeds, a
powerful amplification reaction is generated and results in the
formation of membrane attack complexes (MAC), which generates
pores and causes cell damage. On non-activator host cells,
formation of MAC complexes is prevented by the action of
multiple regulators, like the fluid phase regulators CFHR1, CFHR3,
and factor H, and membrane bound regulators (MCP/CD46), the
serine protease factor I which in the presence of a cofactor results
in the inactivation of C3b and the formation of inactive form of
C3b, i.e., iC3b. Apparently, the components (C3 and Factor B) as
well as these regulators are risk factors for HUS as mutations in




Check for complement activation in serum
(APH50, CH50, decreased C3b levels, 
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Figure 5 | Diagnostic algorithm of atypical HUS according to
Zipfel and Skerka.12 As diagnosis of atypical HUS can be rather
expensive, the rationale for analysis is presented as a hierarchical
order according to a diagnostic algorithm which was recently
proposed.13
Kidney International (2008) 74, 384–388 387
MJ Koziolek et al.: Chronic HUS treated by intermittent plasma exchange t h e r e n a l c o n s u l t
REFERENCES
1. Liu J, Hutzler M, Li C et al. Thrombotic thrombocytopenic purpura (TTP)
and hemolytic uremic syndrome (HUS): the new thinking. J Thromb
Thrombolysis 2001; 11: 261–272.
2. Remuzzi G, Galbusera M, Mannucci PM. ADAMTS13 in microangiopathies.
Blood 2002; 100: 3842.
3. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;
354: 1927–1935.
4. Gasser C, Gautier C, Steck A et al. Ha¨molytisch-ura¨misches Syndrom:
bilaterale Nierenrindennekrosen bei akuten erworbenen ha¨molytischen
Ana¨mien. Schweiz Med Wochenschr 1955; 85: 905–909.
5. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int
1995; 47: 2–19.
6. Noris M, Remuzzi G. Non-shiga toxin-associated hemolytic uremic
syndrome. In: Zipfel P (ed). Complement and Kidney Disease.
Birkhauser-Verlag: Basel, 2005, pp 65–83.
7. Amirlak I, Amirlak B. Hemolytic uraemic syndrome: an overview.
Nephrology (Carlton) 2006; 11: 213–218.
8. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic
purpura and hemolytic uremic syndrome are distinct pathologic entities.
A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127: 834–839.
9. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uraemic
syndrome. Br Med Bull 2006; 77–78: 5–22.
10. Mitra D, Jaffe EA, Weksler B et al. Thrombotic thrombocytopenic purpura
and sporadic hemolytic uremic syndrome plasmas induce apoptosis in
restricted lineages of human microvascular endothelial cells. Blood 1997;
89: 1224–1234.
11. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP,
CFH, and IF mutations on clinical presentation, response to treatment,
and outcome. Blood 2006; 108: 1267–1279.
12. Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic
syndrome. Curr Opin Rheumatol 2006; 18: 548–555.
13. Zipfel PF, Heinen S, Jozsi M et al. Complement and diseases: defective
alternative pathway control results in kidney and eye diseases. Mol
Immunol 2006; 43: 97–106.
14. McRae JL, Duthy TG, Griggs KM et al. Human factor H-related protein 5
has cofactor activity, inhibits C3 convertase activity, binds heparin and
C-reactive protein, and associates with lipoprotein. J Immunol 2005; 174:
6250–6256.
15. Monteferrante G, Brioschi S, Caprioli J et al. Genetic analysis of the
complement factor H related 5 gene in hemolytic uraemic syndrome. Mol
Immunol 2006; 44: 1704–1708.
16. Zipfel PF, Jokiranta TS, Hellwage J et al. The factor H protein family.
Immunopharmacology 1999; 42: 53–60.
17. Zipfel PF, Edey M, Heinen S et al. Deletion of complement factor H-related
genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic
syndrome. PLoS Genet 2007; 3: 387–392.
18. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-Factor H autoantibodies
associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol
2005; 16: 555–563.
19. Hellwage J, Jokiranta TS, Koistinen V et al. Functional properties of
complement factor H-related proteins FHR-3 and FHR-4: binding to the
C3d region of C3b and differential regulation by heparin. FEBS Lett 1999;
462: 345–352.
388 Kidney International (2008) 74, 384–388
t h e r e n a l c o n s u l t MJ Koziolek et al.: Chronic HUS treated by intermittent plasma exchange
